Via antonio magarotto biography
•
Antonio Magarotto
Antonio Magarotto (Pojana Maggiore, 30 giugno – Roma, 10 maggio) è stato un attivista e educatoreitaliano, fondatore dell'Ente Nazionale Sordi e rettore dell'Istituto Statale d'Istruzione Specializzata per Sordi di Padova.
Biografia
[modifica | modifica wikitesto]Figlio di un farmacista padovano, divenne sordo a causa di una meningite che lo colpì all'età di 3 anni. Si trasferì a Siena, per frequentare la scuola per sordi presso l'Istituto "Tommaso Pendola", retto dai Padri scolopi: gli furono insegnati la lettura labiale e il metodo dell'oralismo, e imparò a parlare. Nel ritornò a Pojana dove si dedicò all'arte grafica specializzandosi in linotipia (sulla quale scrisse alcuni libri) e fondando una scuola d'arte.
Trasferitosi a Padova, fu impiegato nella tipografia vescovile dove si stampavano importanti testate d'ispirazione cattolica quali La Libertà, Il Popolo Veneto e la Difesa del Popolo. Lì fondò l'Associazione veneta dei sordomuti e nel
•
Lend Us Your Ears
They are a staple of modern television, and anyone who has watched political speeches or COVID briefings sees their presence: interpreters for the deaf, standing off to the sidelines to translate important information for non-hearing viewers. Indeed, every September 23rd, as per a U.N. resolution in , the International Day of Sign Language (IDSL) is celebrated world-wide. This precedes the already annually observed International Week of the Deaf, which was established back in bygd the World Federation of the Deaf (WFD). And yes, once again, tutte le strade, portano a Roma (“all roads lead to Rome”): the WDF, which fryst vatten, according to its website, “an international, non-governmental organization that acts as a peak body for National Associations of Deaf people”, was co-founded in the Eternal City by two Italian doctors: Vittorio Ierella and Cesare Magarotto.
[Note: Magarotto was the WDF’s general secretary from , the same year the organization relocated its headquarter
•
Published in final edited form as: Clin Cancer Res. Feb 22;25(11)– doi: /CCR
Abstract
Purpose:
BET bromodomain inhibitors have emerged as a promising therapy for numerous cancer types in pre-clinical studies, including Neurofibromatosis Type 1 (NF1)-associated Malignant Peripheral Nerve Sheath Tumor (MPNST). However, potential mechanisms underlying resistance to these inhibitors in different cancers are not completely understood. In this study, we explore new strategy to overcome BET inhibitor resistance in MPNST.
Experimental Design:
Through modeling tumor evolution by studying genetic changes underlying the development of MPNST, a lethal sarcoma with no effective medical treatment, we identified a targetable addiction to BET bromodomain family member BRD4 in MPNST. This served as a controlled model system to delineate mechanisms of sensitivity and resistance to BET bromodomain inhibitors in this disease.
Results:
Here, we sho